TITLE

Harmony COVID-19: a ready-to-use kit, low-cost detector, and smartphone app for

point-of-care SARS-CoV-2 RNA detection

ONE SENTENCE SUMMARY Harmony COVID-19: point-of-care SARS-CoV-2 RNA

detection

AUTHORS

Nuttada Panpradist[1,2], Robert G. Atkinson[1], Michael Roller[1], Enos Kline[1], Qin Wang[1],

Ian T. Hull[1], Jack H. Kotnik[1,3], Amy K. Oreskovic[1], Crissa Bennett[1], Daniel Leon[1],

Victoria Lyon[3], Peter D. Han[4,5], Lea M. Starita[4,5], Matthew J. Thompson[3], Barry R.

Lutz[1]*

AFFILIATIONS

1 Department of Bioengineering,

2 Global Health for Women, Adolescents, and Children, School of Public Health,

3 Department of Family Medicine,

4 Department of Genome Sciences, University of Washington, Seattle, WA, USA

5 Brotman Baty Institute for Precision Medicine, Seattle, WA, USA

* CORRESPONDING AUTHOR

B. R. L. (blutz@uw.edu)

3720 15th Ave NE, Campus Box 355061, Seattle, Washington, United States 98195

ABSTRACT (149 words)

RNA amplification tests allow sensitive detection of SARS-CoV-2 infection, but their

complexity and cost are prohibitive for expanding COVID-19 testing. We developed

"Harmony COVID-19", a point-of-care test using inexpensive consumables, ready-to-

use reagents, and a simple device that processes up to 4 samples simultaneously. Our

lyophilized reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can

detect as little as 15 SARS-CoV-2 RNA copies per reaction, and it can report as early

as 17 min for samples with high viral load (2×10^5 RNA copies per reaction). Analysis of

RNA extracted from clinical nasal specimens (n = 101) showed 95% concordance with

RT-PCR, including 100% specificity in specimens positive for other viruses and

bacteria. Analysis of contrived samples in the nasal matrix showed detection of 92% or

100% in samples with ≥20 or ≥100 particles per reaction, respectively. Usability testing

showed 95% accuracy by healthcare workers operating the test for the first time.

WORD COUNT (9,878 words)

INTRODUCTION

In 2019, an outbreak in China of SARS-CoV-2, the causative pathogen of COVID-19,

rapidly became a global pandemic(*1*), and after a year it has infected 100 million people

and killed 2 million people(*2*). Multiple measures have been used to contain the spread

of COVID-19. Governments imposed universal "stay-home" orders to minimize

transmission(*3*) which in turn has harmed mental health, social life, and the economy(*4*).

It has been proposed(*5*) and demonstrated(*6*) that widespread COVID-19 testing and

contact tracing could be a solution for re-openings, allowing subsets of a community to

resume work and begin to restore the economy. Moreover, testing is essential for re-

opening of international borders. Several countries have enforced a "fit-to-fly" policy;

international travelers must test negative for COVID-19 within 72h before boarding

international flights(*7*). Fast and sensitive point-of-care (**POC**) testing could facilitate the

safe return to functioning domestic and international economies. POC testing could

allow testing to expand to geographic regions that have limited access to centralized

laboratory facilities, enable essential businesses to regularly test employees, and allow

easy and efficient community testing by public health officials and clinics. Importantly,

POC testing is critical in settings that require rapid turnaround time such as emergency

urgent care facilities or points of introduction such as airports.

Here, we report the development of Harmony COVID-19 — a complete moderate-

throughput sample-to-result system for sensitive POC detection of SARS-CoV-2 RNA.

Harmony simplifies testing with ready-to-use assay reagents, an easy-to-use dedicated

smartphone interface, and an inexpensive isothermal heater/detector device to enable

POC testing. The assay includes three redundant SARS-CoV-2 targets to avoid false

negatives due to viral mutation and an internal amplification control (**IAC**) in each test to

avoid false negatives in case of assay failure. The heater/detector detects two-color

real-time fluorescence for the SARS-CoV-2 redundant targets and IAC, and results are

automatically reported on the smartphone. We evaluated the system using two panels

of specimens - a panel of extracted nasal specimens from individuals with respiratory

symptoms, and a blinded panel of contrived specimens from the XPRIZE Rapid Covid

Testing competition – and we conducted usability testing of Harmony by healthcare

workers (**HCWs**). These evaluations have demonstrated that Harmony is a complete

system for sample-to-result testing that is high performance and sufficiently simple for

CLIA-waived settings.

RESULTS

Workflow and operation of COVID-19 Harmony

The Harmony test kit and detector were engineered for low cost and simplicity of use to

enable POC testing (**Fig**.**1a**). The test involves taking a nasal swab, eluting the swab in

a lysis buffer, and transferring the buffer to a reaction tube containing ready-to-use

reagents. The reagent tube is inserted into the custom-designed heater/reader operated

by a cell phone that provides instructions and displays the result.

The Harmony assay uses a unique variation of reverse transcription loop-mediated

isothermal amplification (**RT-LAMP**) that allows fluorescence detection of multiple

targets in the same reaction. The assay amplifies three genomic regions of the SARS-

CoV-2 nucleocapsid phosphoprotein reported by a green fluorescence signal (FAM) and

an engineered internal amplification control (**IAC**) reported by a red fluorescence signal

(TEX 615, alternative for Texas Red®). For samples with no target (**Fig. 1B**, left; NTC),

detection of the IAC confirms that the reaction was functional; absence of target and

IAC indicates a failed reaction. For samples with SARS-CoV-2 RNA (**Fig. 1B**, middle;

200 copies/rxn), the green signal indicates a positive test, regardless of whether IAC is

detected. Harmony using dry reagents detects down to 200 copies of SARS-CoV-2

RNA on a swab (**Fig. 1B**, right; ~20 copies/rxn, corresponding to 0.5 copies/μL). Real-

time detection reports a positive sample as soon as the target signal appears, allowing

detection in <30 min for samples ≥2000 copies per swab (**Fig. 1C**), with earlier results

for higher viral load. The three SARS-CoV-2 targets are reported into the green

fluorescence channel to provide a triply-redundant assay to make it robust against viral

mutations (**Fig. 1D**). A positive test result is reported when any of the three SARS-CoV-

2 targets are present, and a negative test result is reported if SARS-CoV-2 RNA is

undetected, and the IAC is detected. If neither target nor IAC is detected, it indicates a

test failure, and the result is reported as indeterminate (**IND**). **table S1** lists the

sequences of primers/probes used in this RT-LAMP assay.

Development and analytical sensitivity of ready-to-use reagents.

We have developed a lyophilized RT-LAMP mixture that contains primers, sequence-

specific fluorescence probes, IAC DNA template, polymerases, supporting proteins, and

co-factors (**Fig. 2A**) and is activated by adding the nasal swab eluate containing

additional buffer, salts, and detergent. We initially screened excipient formulations that

can preserve enzymatic activity and do not significantly interfere with the primer or

probe behaviors. Mannitol did not drastically impact the core assay compared to

trehalose at the same concentration (**fig. S1**) and did not require increasing the reaction

temperature to maintain the assay speed. Using a commercial real-time thermal cycler,

lyophilized RT-LAMP detected down to 15 RNA copies/rxn (0.38 copies/μL), and IAC

was detected in all negative samples (**Fig. 2B**). RT-LAMP amplification of $2x10^5$ RNA

copies/rxn using the dry reagents generated detectable signal in 17 min (**Fig. 2C**). We

subsequently tested our in-house lyophilized reagents on a larger number of technical

replicates of SARS-CoV-2 RNA at 20 copies/rxn using multiple batches, and 90%

(36/40, 95% confidence interval (**CI**): 76-97%) were amplified (**Fig. 2D**). Medians of time

to detection for FAM and TEX 615 signals were 28.6 min (range: 28.0-29.4) and 31.7

min (range: 31.1-32.7), respectively. In the presence of simulated nasal matrix (salt,

mucin, human DNA), we observed a 10-min delay in amplification of both SARS-CoV-2

RNA and IAC DNA (**Fig. 2E**), but all targets were detected correctly. Greater

interference or other harm to the reaction will further delay IAC amplification; thus, the

IAC serves as an indicator of the reaction's function and can prevent reporting false

negatives due to interference or damaged reagents. By setting a 1-hour reaction time,

the assay can suffer some delay while still correctly identifying positive samples.

Specificity testing against closely-related pathogens MERS and SARS-CoV-1 showed

no cross-reactivity (**fig. S2**).

Hardware: housing and real-time fluorescence reader device

The Harmony system includes a heater/detector device controlled by a dedicated cell

phone and plastic housing with a sample setup station (**Fig. 3A**). The heater/detector

device (**Fig. 3B**) includes an aluminum heater block with four wells and a spring-loaded

heated lid to prevent condensation. A proportional integral derivative (**PID**) feedback

loop running on a microcontroller allows recovery of the temperature setpoint within 3-4

min after disturbance from opening the lid (**Fig. 3C**). Two LEDs (**Fig. 3D**) provide the

excitation light by shining down through the top of each sample tube. Fluorescence

emission passes through holes drilled on the side of the heater block. Each sample well

has an emission filter/photodiode set on each side to detect two emission wavelengths

(**Fig. 3E**). A blue LED (dominant wavelength 470nm) is used to excite FAM, and the

emission photodiode sits behind a dielectric 550nm longpass filter. A yellow LED

(dominant wavelength 587nm) is used to excite TEX 615, and a second emission

photodiode sits behind a 630nm longpass dielectric filter.

Thermostable Inorganic Pyrophosphatase enables real-time LAMP detection in

the Harmony COVID-19 device

RT-LAMP generates inorganic pyrophosphates that precipitate from the solution. The

cloudiness created by precipitates has been used as a visual readout signal for

LAMP(*8*), but here the cloudiness scattered light and caused non-specific signals in

NTC samples (**Fig. 3F,** top) when tested on device. Adding inorganic pyrophosphatase

in the RT-LAMP reaction eliminated built-up pyrophosphate and prevented non-specific

signal in negative reactions (**Fig. 3F,** bottom). Interestingly, this effect was not observed

when the reaction was tested in the commercial thermal cycler (BioRad CFX96).

Multi-purpose Android mobile app: instruction, temperature control, and real-time

analysis of results

The phone software provides interactive guidance for setting up the test. It prompts the

user to input a sample ID by scanning a barcode, capturing a photo, or typing a sample

ID (**Fig. 4, A**-**D**). The software also carries out the closed-loop temperature control for

the heater block and lid heater, and it displays the status of the heater block to prompt

the user to insert the reaction tubes only after the heater reaches the reaction

temperature (**Fig. 4E**). During the test run, the screen displays the test status ("analysis

in progress") and elapsed time, or it reports any detected errors ("failed run") (**Fig. 4F**).

Importantly, the software performs real-time data analysis that detects fluorescence

intensity rise above a dynamically and automatically computed background level.

Signals from SARS-CoV-2 can appear early in the test, especially for high viral loads,

and the real-time analysis allows reporting of positive tests immediately after they are

detected (**Fig. 4G**). Negative results and IND results are reported at the end of the test

run time (**Fig. 4H**). Software analysis is described in the Methods section.

Evaluation using extracted RNA from clinical specimens

Clinical specimens collected from individuals positive for SARS-CoV-2 (*n = 33*) or for

other pathogenic respiratory infections (*n = 68*) were re-tested by RT-qPCR(*9*) to

measure the SARS-CoV-2 viral load and provide the reference test result. Using RT-

qPCR, 68 specimens were confirmed to be SARS-CoV-2 negative (**Fig. 5A,** left), 30

specimens were confirmed to be SARS-CoV-2 positive (**Fig. 5A,** right), and three

previously-positive specimens were only detected by one RT-qPCR assay (either N1 or

N2) and classified as inconclusive (**INC, Fig. 5A,** middle). Specimens were tested in

duplicate on Harmony using the ready-to-use reagents (**Fig. 5A)**, arranged from low to

high virus concentration as determined by RT-qPCR. Out of 30 RT-qPCR-positive

specimens, Harmony detected 25 specimens in both technical replicates and 4

specimens in one of the two replicates. In the three RT-qPCR INC results, one sample

was detected by Harmony in one of the two replicates. Excluding the RT-qPCR INC

specimens and applying a stringent requirement for both Harmony replicates to be

detected to report a positive test, Harmony achieved 95% accuracy (93/98, 95%CI: 88-

98%), 83% sensitivity (25/30, 95%CI: 65-94%), and 100% specificity (68/68, 95%CI: 94-

100%). If replicates are treated independently, Harmony detected 54/60 positive

specimens (90% sensitivity, 95%CI: 79-96%). For specimens with ≥10 copies/rxn,

Harmony detected 24/25 specimens (96% sensitivity, 95%CI: 80-100%), and for

specimens with ≥40 copies/rxn, Harmony detected 18/18 specimens (100% sensitivity,

95%CI: 81-100%).

The clinical panel (**Fig. 5A**) included 68 specimens that were SARS-CoV-2 negative but

contained other respiratory pathogens including influenza, rhinovirus, and seasonal

coronavirus (**Fig. 5B**). Harmony correctly identified 68/68 specimens (**Fig. 5A,** left) as

negative (100%, 95%CI: 94-100% specificity). **Fig. 5C** summarizes the performance of

the extracted clinical specimens.

Evaluation of contrived SARS-CoV-2 viral particle specimens without extraction A

panel of 69 contrived samples from the COVID-19 XPRIZE competition were tested on

the Harmony system with ready-to-use reagents (**Fig. 5**, **D** and **E**). For SARS-CoV-2

virus in PBS, Harmony detected 100% of samples containing ≥50 SARS-CoV-2 viral

particles/rxn, and 89% of samples containing ≥20 viral particles/rxn in PBS (despite

PBS being a non-ideal buffer). In nasal matrix, Harmony COVID-19 detected 100% of

samples containing ≥100 viral particles/rxn, and 92% of samples containing ≥20 viral

particles/rxn. In human saliva, Harmony detected 100% of samples with ≥250 viral

particles/rxn and 58% with ≥20 viral particles/rxn. Harmony had zero false positives

across all samples.

Feasibility testing: sample-to-result system tested by healthcare workers and

laboratory personnel

To complete the system, we developed a test kit that included all components needed

for running a test, including the swab, elution buffer, a fluid transfer device, and a ready-

to-use reagent tube. Swabs were pre-loaded with SARS-CoV-2 DNA to serve as a

control sample to evaluate performance by HCWs and laboratory personnel (**LPs**).

In the first phase of user testing (**Fig. 6A**), we compared the accuracy and

reproducibility of two methods for transferring the eluate to the reaction tube when

operated by LPs *(n = 5)* and HCWs (such as nurses, medical students, and dental

students; *n = 10*). The first method (**Fig. 6B** and shown-previously in **Fig. 1**) used a

unified sampler-dispenser. The second method (**Fig. 6C**) used a transfer pipette to

transfer a fixed volume of fluid to the reaction tube. Regardless of the baseline skill of

operators, transfer pipettes yielded more reproducible recovered volumes than the

unified dispenser (F-test, p <0.001). Recovered volumes of the two methods were not

significantly different between HCWs and LPs (student's t-test, two-sided, p = 0.90; **Fig.**

6D). User feedback on the transfer methods and preferences on tube sizes are

summarized in **table S2**.

Next, HCWs and LPs executed the full Harmony workflow on contrived SARS-CoV-2

DNA swab samples (**Fig. 6**). Using the transfer pipette workflow (**Fig. 6E**), the test

accuracy was 100% (10/10) for LPs and 95% (19/20) for HCWs. Surprisingly, we found

that the HCWs performed better than the LPs when using the unified dispenser system

(**Fig. 6F**), both accuracy and IND rates. HCWs had significantly lower (Z-test, two-tailed,

p<0.05) IND results (1/20) than LPs (3/10) when using the unified dispenser system.

Excluding IND results, the HCWs had 89% accuracy, higher than LPs with 71%

accuracy (Z-test, two-tailed, p <0.05), when using the unified dispenser system.

DISCUSSION

This work presents a combination of multi-disciplinary engineering (molecular,

mechanical, electrical, software, human interface design) to develop a complete system

for SARS-CoV-2 detection at the POC. The system is inexpensive and simple yet has

features comparable to laboratory-based tests (**Table 1A**). The assay has high

sensitivity and specificity in clinical and contrived specimens, and HCWs successfully

performed the workflow with high accuracy.

Harmony uses ready-to-use reagents that improve speed and accuracy for assay setup.

Unlike other lyophilized RT-LAMP[25], our lyophilized reagents are magnesium-free,

which prohibits any enzymatic activity that may occur before assay initiation. Our

lyophilized RT-LAMP is activated upon the addition of sample which contains

magnesium and detergent. Thus, it should be less prone to moisture degradation than

magnesium-containing lyophilized RT-LAMP.

The lyophilized Harmony assay detected as low as 15 copies/rxn of synthetic SARS-CoV-

2 RNA and detected all extracted RNA samples from clinical specimens at ≥40 copies/rxn.

Here, we used only 10μL RNA in 40μL reaction to allow head-to-head sensitivity

comparison to the CDC RT-PCR protocol that uses 5μL RNA in a 20μL reaction. The

lyophilized reagents can accommodate up to 40µL of sample (4x than used here), which

could further increase Harmony sensitivity.

Harmony lyophilized RT-LAMP is robust against simulated nasal matrix containing

mucin, salt, and human genomic DNA. The impact of salts and mucin was observed as

a delayed reaction time for both target and IAC. To account for this delay, we adjusted

the assay time to 90 min when analyzing specimens with nasal matrix. We found

excellent sensitivity when testing samples with ≥50 viral particles in nasal matrix

(estimated 1250 copies/swab for 1mL elution buffer and 40µL reaction), which would be

sufficient to detect SARS-CoV-2 in most nasal specimens (10^3-10^9 SARS-CoV-2

copies/swab) from individuals within the first 3-5 days after the symptom

onset[26]. Further, Harmony detected all samples with ≥100 viral particles in nasal matrix

(estimated 2500 copies/swab for 1mL elution buffer and 40µL reaction). While saliva

was not our intended specimen type, we found a moderate sensitivity when testing the

XPRIZE blinded saliva panel. Heat treatment of saliva shown to enable detection by RT-

PCR[27] would likely improve the sensitivity of our RT-LAMP in detecting SARS-CoV-2 in

saliva.

Isothermal amplification, like RT-LAMP in Harmony, is often promoted as ideal for POC

testing because it can be carried out using a constant temperature heat source, such as

a water bath, heat block, or even more novel sources (chemical heat source, sunlight,

body temperature)(*10*). However, reported tests often have other limitations that may

prevent their use in POC testing (**Table 1B**). Common limitations include use of

reagents use of refrigerated or frozen reagent stocks that must be formulated using

laboratory pipettes, manual steps for sample processing that require laboratory skill, or

detection steps that rely heavily on user interpretation or analysis by a user's cell phone.

Harmony is a complete sample-to-result system that uses ready-to-use reagents for

simple 1-minute setup and a dedicated device that reports results without extra post-

amplification steps or reliance on user interpretation.

Some RT-LAMP tests use end-point lateral flow strips for detection[28], which adds a user

step, but more importantly, should not be done at the POC because it exposes the

testing site to amplicons that will give false positive results in subsequent tests. Others

use in-tube detection by eye(*11*),(*11*) or using a cell phone(*12*) which increases the user

burden and could introduce additional sources of error. Real-time detection used in

Harmony COVID-19 removes the need for extra detection steps or user interpretation.

Real-time detection also allows Harmony to report positive results as soon as the

SARS-CoV-2 signal appears rather than waiting for an end-point detection method.

High viral load samples could be detected in as little as 20 min, which could enable

more timely infection control measures to limit viral spread. Harmony real-time detection

allows testing without opening tubes after amplification, requires no extra steps or

interpretation by the user, and allows reporting a positive sample earlier than end-point

detection methods.

The Harmony device automates heating, multiplexed detection, and data interpretation.

We integrated a simple heater with low-cost LEDs and sensors to enable real-time two-

color detection of RT-LAMP fluorescence in four independent sample wells. The device

costs <US$300 in parts for prototypes, while the lowest cost commercial RT-PCR

machine on the market is >US$5000(13). Moreover, the Harmony device is portable

and energy-efficient, requiring <15 watts and operable by USB power sources. These

features are attractive for use at the POC in the U.S. and resource-limited settings.

Lastly, the simple workflow and analysis of Harmony is appropriate for POC testing.

Test operation involves a few simple steps that take ~1 minute, and there are no further

user steps after starting the test. Here, HCWs were able to operate the tests without

training using only simple written instructions and watching the procedure on video. The

simplicity of the Harmony procedure and completeness of the stand-alone system can

be a significant advantage for onboarding to ambulatory care settings and potentially

community testing locations.

In this study, we evaluated the system using RNA extracted from clinical samples stored

in viral transport medium (**VTM**) and contrived specimens in unknown nasal and saliva

matrix (XPRIZE), which may not reflect performance in fresh clinical samples. These

samples were used due to the difficulty of obtaining fresh dry swabs intended for this

POC test, and RNA was extracted from clinical samples because VTM is irrelevant for

immediate testing at the POC. Nevertheless, this testing shows excellent analytical

reactivity to clinical specimens, lack of cross-reactivity with other respiratory pathogens,

analytical sensitivity comparable to the CDC RT-PCR, and resilience in the presence of

nasal matrix.

While our assay is relatively fast and sensitive, there is potential to improve

performance. We ran RT-LAMP at 64°C, which is 9°C above the optimal temperature

for the RT enzyme. We hypothesize that cooling of the heat block when the lid is open,

followed by a few minutes to ramp back up to 64°C, provided an opportunity for the RT

enzyme to operate. In contrast, the reaction speed of the temperature-stable DNA

polymerase in this assay is optimal at higher temperature. Thus, operating the device

with an initial 55°C step for optimal RT activity followed by a higher temperature step for

fast DNA amplification could increase sensitivity and/or speed.

The current design of RT-LAMP assay can be improved to include an IAC that is more

representative of the SARS-CoV-2 virus. We currently use a DNA IAC, which has been

used in several EUA assays[34], but the DNA control does not capture the potential failure

of the lysis and cDNA conversion processes. We are developing a new IAC that uses

RNA that can be packaged in a viral envelope. This modification may require re-

development of excipients that preserve the RT-LAMP enzymes and the enveloped

RNA.

POC tests like Harmony could provide rapid testing to enable the re-opening of

businesses, schools, and borders; but the need for POC testing extends beyond the

current emergency. As natural immunity and vaccination take hold, COVID-19 is likely

to become endemic with seasonal outbreaks. Tests such as Harmony will be necessary

not only to help identify individuals with SARS-CoV-2, but other respiratory pathogens

such as influenza and RSV, as the symptoms of these are similar. Prior to the current

SARS-CoV-2 pandemic, the yearly influenza infections caused nearly 30 million cases

in the U.S. alone, with 400,000 hospital admission and 35,000 deaths(*14, 15*). Indeed,

particularly when more typical patterns of respiratory infections occur, there will be a

need for tests that can perform multiplex testing for individuals presenting respiratory

symptoms. Tests such as Harmony will become a common practice for confirming

presence of viral infections that can be treated with antiviral therapies or that demand

infection control, as well as helping to reduce inappropriate use of antibiotics. Further,

test platforms developed for this pandemic could be more readily adapted to detect new

diseases to increase readiness for future pandemics. The advances in awareness and

acceptance of testing for infections at scale, and the technology platforms developed

will have ongoing benefit for COVID-19 control, reducing harm from other endemic

diseases, and fighting future pandemics.

MATERIALS AND METHODS

Preparation of synthetic RNA standards

MERS and SARS-CoV-1 plasmid standards (10006623 and 10006624, Integrated DNA

Technologies, Coralville, IA) were amplified using M13 PCR primers to generate DNA

templates tagged with T7 promoter sequences. DNA templates containing T7 promoter

sequences were transcribed using Hi-T7 RNA polymerase (M0658, New

England Biolabs, Lawley, MA) following the manufacturer's protocol, with 1 U/μL RNase

inhibitor (N2611, Promega, Madison, WI). Following transcription, 0.01U/μL DNase I

(EN0521, ThermoFisher Scientific, Waltham, MA) was added to each reaction, and

incubated at 37°C for 15 min. RNA transcripts were purified with Monarch RNA Cleanup

Kits (T2040, New England Biolabs). RNA was quantified on a Qubit 4 fluorometer

(Q32852, RNA HS Assay Kit, ThermoFisher Scientific, Waltham, MA), and checked for

length and integrity by electrophoresis on TapeStation (5067 RNA screening tape,

Agilent Technologies, Santa Clara, CA). RNA at 10^{10} copies/μL was stored in nuclease-

free water in single-use aliquots. SARS-CoV-2 RNA was prepared and quantified as

previously described(*16*).

In-house polymerase production

Plasmid preparation: The chimeric polymerase (TFv1) was generated by assembly

PCR using genomic material from *Thermus thermophilus* HB27 (ATCC BAA-163D-5™,

Gaithersburg, MD) and a synthetic gene fragment derived from *Thermodesulfatator*

indicus (*T. in*), (Integrated DNA Technologies, Coralville, IA), similar to the method

previously described(*17*). Briefly, a 3' terminal fragment of the *T.th* HB27 **PolA** gene

downstream of the finger domain was amplified by PCR using Phusion® Hot Start Flex

DNA Polymerase (M0535L, New England Biolabs) with a modified forward primer

containing sequence overlap with the *T. in polA* gene fragment *(AA734-795,* codon

optimized for *E. coli)*. A chimeric sequence was then generated by assembly PCR. A

second*T.th* polymerase fragment, upstream of the finger domain and lacking the 3´to 5´

exonuclease domain, was similarly amplified and appended to the 5' end of the chimeric

fragment. The resultant sequence corresponds to a *T. th* DNA polymerase I fragment,

orthologous to the Stoffel fragment of *T.aq.* polymerase, with a replacement in the finger

domain derived from *T. in*. This gene was then cloned into the expression vector pET

His6 TEV LIC cloning vector (2B-T) (a gift from Scott Gradia, Plasmid # 29666,

Addgene, Watertown, MA) by ligation independent cloning(*18*). The annealed vector

and insert were transformed into T7 Express lysY/Iq Competent *E.* coli (C2987H, New

England Biolabs) per the manufacturer's protocol and plated on LB 100μg/mL

carbenicillin plates. Colony plasmid inserts were verified by Sanger sequencing.

Protein expression and purification: 50mL starter culture in LB broth with 100μg/mL

carbenicillin was inoculated with a sequence-verified colony and incubated at 30°C

overnight in a shaking incubator at 200rpm. The culture was centrifuged at 5,000 RCF

for 15 min and resuspended in an equivalent volume fresh LB carbenicillin media.

Flasks of 500mL LB broth with 100μg/mL carbenicillin were inoculated with 5mL of

resuspended starter culture and incubated at 37°C in a shaking incubator at 200rpm

until OD_{600} of 0.4-0.6 had been achieved. Cultures were induced with 0.4mg/mL of IPTG

and incubated for two hours then harvested by centrifugation at 5,000 RCF for 15 min,

decanted, and stored as cell pellets at –80°C until needed. Prior to purification, cell

pellets were resuspended in lysis buffer (20mM sodium phosphate pH7.4, 80mM NaCl,

1%*(v/v)* Triton (648466 Sigma, St. Louis, MO), and 1mg/mL lysozyme from chicken egg

white (Millipore Sigma, Burlington, MA)). Suspensions were heated at 37°C for 20 min,

then lysed by ultrasonic disruption using a Fisherbrand™ Model 120 Sonic

Dismembrator (Fisher Scientific, Waltham, MA) with two cycles of two second pulses at

50% amplitude for 2 min, while on ice. Lysates were heat-clarified at 65°C for 20 min,

followed by centrifugation at 20,000 RCF. The supernatant was collected and diluted

1:6 with sample diluent buffer (20mM sodium phosphate, 1.8M NaCl, pH 7.4) and

filtered with a 0.22 μm syringe filter (25-342 Olympus, Genesee Scientific, San Diego,

CA). The Purified clarified lysate was applied to a 1mL Hitrap Talon Crude column

(Cytiva, Marlborough, MA) and enriched per manufacturers default recommended

specifications using an ÄKTA start system with the Frac30 fraction collector (Cytiva).

Elution fractions were evaluated by A_{280} on a spectrophotometer (2200 Nanodrop,

Fisher Scientific) using the proteins expected molecular weight (63.062kDa) and

extinction coefficient (60,850m^2/mol) of the His-tagged polymerase. Elution fractions

containing protein were diluted 1:10 with 10mM sodium phosphate and applied to a 1mL

HiTrap® Heparin HP column and purified per the manufacturers recommended

specifications except for a modified binding buffer (10mM sodium phosphate, and

30mM NaCl, at pH 7). Fractions containing protein were concentrated and buffer

exchanged into storage buffer (17mM Tris-HCl, 167mM KCl, 17% glycerol pH7.5) using

an Amicon® Ultra-2 30K device (Millipore Sigma), as recommended by the

manufacturer. The recovered polymerase solution was then adjusted to 10mM Tris-HCl,

100mM KCl, 2mM DTT, 0.1%Triton X-100, 50%glycerol pH7.5. Polymerase purity was

evaluated by SDS-PAGE and spectrophotometry throughout purification.

RT-LAMP assay design

Alignment of SARS-CoV-2 sequences (available on NCBI up to January 2020) were

performed using Geneious (Auckland, New Zealand). Three sets of LAMP primers

(Harmony NC1, Harmony NC2, and Harmony NC3) were developed targeting the

22,285 – 28,517 (232 bases), 28,528 – 28,471 (213 bases), and 29,135 – 29,416 (281

bases) regions of the SARS-CoV-2 nucleocapsid phosphoprotein gene. *In-slico* analysis

showed that this primer design matched 100% of SARS-CoV-2 sequences and did not

have cross-reactivity to MERS and SARS-CoV-1. We used two detection probes, each

comprised of a fluorescent probe and its complementary quencher probe. For detection

of SARS-CoV-2 RNA amplification, we used FAM labeled detection probe and Iowa

Black™ quencher probe. For detection of IAC amplification, we used TEX 615 labeled

detection probe and BHQ2 labeled quencher probe. The primer and probe sequences

are listed in **table S1**.

Lyophilization of RT-LAMP reagents

Reactions containing 2x primers (3.2mM each FIP/BIP primer, 0.4mM each loop primer,

and 0.8mM each F3/B3 primer) and probes (0.4mM fluorophore probes and 0.6mM

quencher probes) in the presence of 5% *(v/v)* mannitol (OPS Diagnostics EXMN 500-

01), 10mM DTT, 1.4μg DNA polymerase, 1.2U/μL WarmStart RTx (M0380L, New

England Biolabs), 2.8mM each dNTP in 10mM Tris-HCl, pH 7.4, 2U/μL RNase inhibitor

(N2615, Promega), 50mU/μL thermostable inorganic pyrophosphatase (M0296L, New

England Biolabs), and 2500 copies/μL IAC DNA were prepared in 20μL aliquots of

0.2mL reagent tubes and lyophilized. Packages were stored in desiccant packets at -

20°C until use.

RT-LAMP reaction setup

Lyophilized reagents were resuspended in a final volume of 40μL containing 1x

rehydration buffer (ThermoPol buffer (B9004S, New England Biolabs), 6mM MgSO$_4$,

and 0.5%*(v/v)* Triton X-100). For analytical sensitivity experiments, 2μL SARS-CoV-2

RNA in water was added. For clinical testing, 10μL extracted RNA was added to each

RT-LAMP reaction. For testing the contrived specimens, 10μL sample (not extracted)

was added to each RT-LAMP reaction. For usability testing, 40μL swab eluate was

added directly to the RT-LAMP reaction using transfer pipettes or the in-house unified

dispensers.

Analytical sensitivity of RT-LAMP assay

Analytical sensitivity of lyophilized RT-LAMP was tested using purified RNA (0-2x10^6

copies/40μL reaction). We also tested the effect of salt, human DNA, and mucin on

amplification of SARS-CoV-2 RNA and IAC DNA using simulated nasal matrix as

previously described(*19*).

Preparation of contrived swab samples and kits for usability testing

For the transfer pipette workflow, each kit contained one swab (either positive or

negative), a vial of buffer (10-500-25, Fisher Scientific, Waltham, MA) containing 400μL

of 1x rehydration buffer (see section RT-LAMP reaction setup) and one lyophilized RT-

LAMP reagent tube. For positive swabs, 10μL of 100 copies/μL SARS-CoV-2 DNA in

0.05% Triton X-100 was pipetted onto the swab (1804-PF, Puritan Medical) and dried at

room temperature in the air-clean chamber (825-PCR/HEPA, Plas-Labs, Lansing, NI)

for 4 hours before packaging in a sealed foil pouch with desiccant (S-8032, ULINE). The

unified sampler was built from parts using an assembly jig (custom order from Hygiena,

LLC, Camarillo, CA). The unified dispenser contained a hollow-shaft polyurethane swab

attached to a bulb preloaded with 400μL 1x rehydration buffer and a separate tube with

a filter and drip dispenser friction fit inside the tube. Each custom sampler kit contained

an in-house assembled dispenser unit and one lyophilized RT-LAMP reagent tube.

Usability study

The Harmony usability study was approved by the Institutional Review Board at the

University of Washington (IRB#: STUDY00010884), and informed consent was provided

by participants. HCWs (*n = 10*), including registered nurses, medical students, and

dental students were enrolled in this study over the course of 1 month. All data was

collected without identifiers. The primary objective of this study was to determine the

accuracy and precision of the two sample transfer methods and test if variation in

reproducibility impacted assay performance, and the secondary objective was to gather

user input on the feasibility of each protocol. Participants first received an explanation of

the test and its intended use, then watched an instructional video narrated by the

facilitator to become familiar with the Harmony workflow (**video S1 and video S2**). After

watching the video, participants were given a packet with a unique identifier that

contained comprehensive instructions for the study procedures and survey questions.

Study procedures were modeled on a coaching methodology(*20*), to allow natural

progression of the procedures and to identify blocking steps in the instructions. The

facilitator sat 10 feet from the participant and kept a record of verbal questions and

comments from participants but did not provide answers to procedural questions unless

the participant was could not proceed.

For part 1, data related to user preference on sample preparation, tube sizes, and their

level of confidence in performing each task were collected anonymously as prompts

within their study packet. Open-ended questions were extracted for themes in errors or

issues and supplemented with comments and observations recorded by the facilitator.

Samples were saved with deidentified labels, and after all participants had completed

the study facilitators measured volumes in each receiving tube from part 1. The

variances of the volume recovered by each method were tested for their equality using

F-Test, and the P-value was reported. The means of the recovered volumes transferred

by LPs or HCWs were compared using student's t-test (two-sided), and the P-value was

reported.

For part 2, each participant followed instructions in the packet and on the integrated

mobile phone to complete the entire Harmony workflow on four total contrived samples,

two samples using the transfer pipette protocol and two using the unified sampler

system. Kits were prepared as specified above.

The lab personnel ($n = 5$) portion of the user testing aimed to compare performance of

the Harmony device by HCW to that of an "experienced" population, by replicating this

process with four students and a researcher from the Lutz Lab. Survey questions were

omitted for this group because these volunteers provided feedback throughout the

development of Harmony and their views are included in the discussion of this

manuscript. The accuracies of tests performed by LPs and HCWs using each method

were tested for their equality using Z-test (two-sided), and the P-value was reported.

Clinical nasal swab specimens from individuals presenting respiratory symptoms

A minimum sample size of 30 (each negative and positive) was required to achieve the

confidence interval (**CI**) of 90 -100% (binomial cumulative distribution function) should

all results be accurate. Our clinical specimen panel (*n = 110*) was previously used to

evaluate other SARS-CoV-2 assays(*16*), but 9 specimens had insufficient volume for

RNA extraction and were thus excluded from the study. These specimens were

collected with informed consent as part of the Seattle Flu Study, approved by the

Institutional Review Board at the University of Washington (IRB#: STUDY0006181). All

participant specimens were de-identified prior to the transfer to the Lutz lab at the

University of Washington for analysis. The remaining 101 specimens were evaluated

using the newly-extracted RNA for analysis by RT-qPCR and Harmony system, to avoid

variations introduced from different batches of extraction. RNA was extracted

from clinical nasal swab specimens stored in viral transport media using

the QIAamp Viral RNA Mini Kit (52906; Qiagen, Hilden, Germany). Prior to extraction,

100μL of each specimen was mixed with 40μL negative VTM to reach the suggested

140μL sample volume. RNA was extracted according to the manufacturer's

protocol, eluted into 70μL of EB buffer, and stored at -80°C in single-use aliquots until

amplification. 5μL of RNA was used for analysis in 20μL RT-qPCR using U.S. CDC N1,

N2, or RP human control assays(*9*). 10μL of RNA was used for analysis in 40μL

lyophilized RT-LAMP in the Harmony workflow. Each sample was run in duplicate. Only

samples with positive results from both Harmony replicates were reported as positive for

SARS-CoV-2. Sensitivity (TP/(TP + FN)), specificity (TN/(TN+FP)), and concordance

((TP+TN)/(TP+TN+FP+FN)) were calculated and reported with 95%CI using binomial

exact proportions.

XPRIZE blinded contrived sample panel

The blinded panel was assembled and distributed by HudsonAlpha Discovery

(Huntsville, AL) for COVID-19 XPRIZE competition, and information on the samples was

revealed to the authors only after results were submitted to XPRIZE. Samples were

shipped to the Lutz Lab at the University of Washington. We reported results for

contrived samples of chemically-inactivated SARS-CoV-2 viral particle (ZeptoMetrix

Corporation, Buffalo, NY) spiked in phosphate-buffered saline (**1x PBS**) (*n = 29*), nasal

specimens (*n = 20*), or saliva (*n = 20*) at 0 to 1000 copies/rxn. To affirm the identify of

these specimens, we also performed RT-qPCR using CDC primer/probes after the

samples had been tested using the Harmony system.

Housing

The housing combines the heater/reader assembly with the cell phone, while concealing

the connector cables and presenting a sturdy and easy-to-us0e platform. The 3D CAD

program, Fusion 360 (AutoDesk), was used for the design of housing. Prototypes were

printed in PLA plastic (Overture™ Filament) using a Prusa i3 MK3s at 0.3mm layer

height. Power was supplied to both the heater/reader assembly and the phone

simultaneously using the Charge-Plus USB-C (LAVA Computer Manufacturing

Inc.) connector device and a standard fast-charging American cellphone charger. The

LAVA device also facilitates the transfer of data between the devices.

Reader/heater device

The aluminum block to house the reagent tubes was custom-made by Bryan

Willman according to the specifications in **fig. S3**. The circuit boards were designed

using Autodesk Eagle (San Rafael, CA), and the assembly of the circuit boards are

shown in **fig. S4** and **fig. S5**. The lid, latch, and upper and lower housing of the device

were drawn using SolidWorks (Dassault Systèmes, Waltham, MA) and printed by

Xometry - HP MultiJet Fusion 3D (Gaithersburg, MD). All parts were assembled as

shown in **fig. S6**.

Real-time fluorescence signal analysis

After the user inserts the reaction tube into the device, the software adjusts the

temperature to re-equilibrate the temperature of heat block back to the reaction

temperature. During this initial period, the signals from the photo diodes (the blue LED

(FAM signal for target amplification) and the yellow LED (TEX 615 signal for the IAC

amplification) are collected but not used in analyses. Once the initial period is over,

signal analysis commences. Each signal is analyzed in real time by comparing the

current mean of the signal over the most recent 60s interval to the signal's behavior

some 360s in the past. Specifically, the current mean is compared to a bound consisting

of the signal's mean over the period from 420s to 360s in the past plus a multiple (1.9x

for target, 1.5x for IAC) of the signal's sample standard deviation over that same period.

If the current mean exceeds the bound, and maintains that condition for at least 15s, the

signal is said to have "indicated". If the signal from the target emission indicates, the

presence of SARS-CoV-2 has been detected, and the software immediately reports

"positive COVID-19". If the signal from the IAC emission indicates, successful

amplification of the IAC has been detected. Then, if the target emission does not also

indicate before the end of the run, then a "negative COVID-19" result is reported; this

delay in reporting negative results provides the maximum opportunity to detect low

concentrations of SARS-CoV-2 that may be present in samples. If neither the target

emission nor the IAC emission is detected, "test failed" is reported.

REFERENCES AND NOTES

1.   World Health Organization. (2020), vol. 2021.

2.   World Health Organization. (2021), vol. 2021.

3.   A. Sandford. (Euronews with AP, AFP, 2020).

4.   G. Bonaccorsi, F. Pierri, M. Cinelli, A. Flori, A. Galeazzi, F. Porcelli, A. L.

Schmidt, C. M. Valensise, A. Scala, W. Quattrociocchi, F. Pammolli, Economic

and social consequences of human mobility restrictions under COVID-19. *Proc

Natl Acad Sci U S A* **117**, 15530-15535 (2020).

5.   I. Y. Chu, P. Alam, H. J. Larson, L. Lin, Social consequences of mass quarantine

during epidemics: a systematic review with implications for the COVID-19

response. *J Travel Med* **27**, (2020).

6.   J. Garre-Olmo, O. Turro-Garriga, R. Marti-Lluch, L. Zacarias-Pons, L. Alves-

Cabratosa, D. Serrano-Sarbosa, J. Vilalta-Franch, R. Ramos, G. Girona Healthy

Region Study, Changes in lifestyle resulting from confinement due to COVID-19

and depressive symptomatology: A cross-sectional a population-based study.

Compr Psychiatry **104**, 152214 (2021).

7.   Centers for Diseases Control and Prevention. (2021), vol. 2021.

8.   Y. Mori, K. Nagamine, N. Tomita, T. Notomi, Detection of loop-mediated

isothermal amplification reaction by turbidity derived from magnesium

pyrophosphate formation. *Biochem Biophys Res Commun* **289**, 150-154 (2001).

9.   U.S. Centers for Disease Control and Prevention, "CDC 2019-Novel Coronavirus

(2019-nCoV) Real-Time RT-PCR Diagnostic Panel For Emergency Use Only,"

(2020).

10.   P. Craw, W. Balachandran, Isothermal nucleic acid amplification technologies for

point-of-care diagnostics: a critical review. *Lab Chip* **12**, 2469-2486 (2012).

11.   E. Gonzalez-Gonzalez, I. M. Lara-Mayorga, I. P. Rodriguez-Sanchez, Y. S.

Zhang, S. O. Martinez-Chapa, G. T. Santiago, M. M. Alvarez, Colorimetric loop-

mediated isothermal amplification (LAMP) for cost-effective and quantitative

detection of SARS-CoV-2: the change in color in LAMP-based assays

quantitatively correlates with viral copy number. *Anal Methods* **13**, 169-178

(2021).

12.   J. Rodriguez-Manzano, K. Malpartida-Cardenas, N. Moser, I. Pennisi, M. Cavuto,

L. Miglietta, A. Moniri, R. Penn, G. Satta, P. Randell, F. Davies, F. Bolt, W.

Barclay, A. Holmes, P. Georgiou, Handheld Point-of-Care System for Rapid

Detection of SARS-CoV-2 Extracted RNA in under 20 min. *ACS Cent Sci* **7**, 307-

317 (2021).

13.   Chaibio. (Santa Clara, CA, 2021).

14.   W. Putri, D. J. Muscatello, M. S. Stockwell, A. T. Newall, Economic burden of

seasonal influenza in the United States. *Vaccine* **36**, 3960-3966 (2018).

15.   Centers for Diseases Control and Prevention. (2012).

16.   N. Panpradist, Q. Wang, P. S. Ruth, J. H. Kotnik, A. K. Oreskovic, A. Miller, S. W.

A. Stewart, J. Vrana, P. D. Han, I. A. Beck, L. M. Starita, L. M. Frenkel, B. R.

Lutz, Simpler and faster Covid-19 testing: Strategies to streamline SARS-CoV-2

molecular assays. *EBioMedicine* **64**, 103236 (2021).

17.   N. Morant, University of Bath, (2015).

18.   Addgene. (Watertown, Massachusetts, USA, 2021), vol. 2021.

19.   N. Panpradist, B. J. Toley, X. Zhang, S. Byrnes, J. R. Buser, J. A. Englund, B. R.

Lutz, Swab sample transfer for point-of-care diagnostics: characterization of

swab types and manual agitation methods. *PLoS One* **9**, e105786 (2014).

20.   R. Mack, J. B. Robinson, in *The Psychology of Expertise,* H. R.R., Ed. (Springer,

New York, NY, 1992), pp. 245-268.

21.   FPbase. (2021), vol. 2020.

22.   Newport. (2021), vol. 2021.

23.   Mousers Electronics. (2021), vol. 2021.

24.   A. Alekseenko, D. Barrett, Y. Pareja-Sanchez, R. J. Howard, E. Strandback, H.

657   Ampah-Korsah, U. Rovsnik, S. Zuniga-Veliz, A. Klenov, J. Malloo, S. Ye, X. Liu,

658   B. Reinius, S. J. Elsasser, T. Nyman, G. Sandh, X. Yin, V. Pelechano, Direct

659   detection of SARS-CoV-2 using non-commercial RT-LAMP reagents on heat-

660   inactivated samples. *Sci Rep* **11**, 1820 (2021).

661   25.   B. A. Rabe, C. Cepko, SARS-CoV-2 detection using isothermal amplification and

662   a rapid, inexpensive protocol for sample inactivation and purification. *Proc Natl*

663   *Acad Sci U S A* **117**, 24450-24458 (2020).

664   26.   S. Wei, E. Kohl, A. Djandji, S. Morgan, S. Whittier, M. Mansukhani, E. Hod, M.

665   D'Alton, Y. Suh, Z. Williams, Direct diagnostic testing of SARS-CoV-2 without the

666   need for prior RNA extraction. *Sci Rep* **11**, 2402 (2021).

667   27.   V. L. Dao Thi, K. Herbst, K. Boerner, M. Meurer, L. P. Kremer, D. Kirrmaier, A.

668   Freistaedter, D. Papagiannidis, C. Galmozzi, M. L. Stanifer, S. Boulant, S. Klein,

669   P. Chlanda, D. Khalid, I. Barreto Miranda, P. Schnitzler, H. G. Krausslich, M.

670   Knop, S. Anders, A colorimetric RT-LAMP assay and LAMP-sequencing for

671   detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med* **12**, (2020).

672   28.   L. Bokelmann, O. Nickel, T. Maricic, S. Paabo, M. Meyer, S. Borte, S.

673   Riesenberg, Point-of-care bulk testing for SARS-CoV-2 by combining

hybridization capture with improved colorimetric LAMP. *Nat Commun* **12**, 1467

(2021).

29.   W. Yamazaki, Y. Matsumura, U. Thongchankaew-Seo, Y. Yamazaki, M. Nagao,

Development of a point-of-care test to detect SARS-CoV-2 from saliva which

combines a simple RNA extraction method with colorimetric reverse transcription

loop-mediated isothermal amplification detection. *J Clin Virol* **136**, 104760

(2021).

30.   J. Qian, S. A. Boswell, C. Chidley, Z. X. Lu, M. E. Pettit, B. L. Gaudio, J. M.

Fajnzylber, R. T. Ingram, R. H. Ward, J. Z. Li, M. Springer, An enhanced

isothermal amplification assay for viral detection. *Nat Commun* **11**, 5920 (2020).

31.   M. Patchsung, K. Jantarug, A. Pattama, K. Aphicho, S. Suraritdechachai, P.

Meesawat, K. Sappakhaw, N. Leelahakorn, T. Ruenkam, T. Wongsatit, N.

Athipanyasilp, B. Eiamthong, B. Lakkanasirorat, T. Phoodokmai, N. Niljianskul,

D. Pakotiprapha, S. Chanarat, A. Homchan, R. Tinikul, P. Kamutira, K.

Phiwkaow, S. Soithongcharoen, C. Kantiwiriyawanitch, V. Pongsupasa, D.

Trisrivirat, J. Jaroensuk, T. Wongnate, S. Maenpuen, P. Chaiyen, S.

Kamnerdnakta, J. Swangsri, S. Chuthapisith, Y. Sirivatanauksorn, C. Chaimayo,

R. Sutthent, W. Kantakamalakul, J. Joung, A. Ladha, X. Jin, J. S. Gootenberg, O.

O. Abudayyeh, F. Zhang, N. Horthongkham, C. Uttamapinant, Clinical validation

of a Cas13-based assay for the detection of SARS-CoV-2 RNA. *Nat Biomed Eng*

4, 1140-1149 (2020).

32. J. Joung, A. Ladha, M. Saito, M. Segel, R. Bruneau, M. W. Huang, N. G. Kim, X.

Yu, J. Li, B. D. Walker, A. L. Greninger, K. R. Jerome, J. S. Gootenberg, O. O.

Abudayyeh, F. Zhang, Point-of-care testing for COVID-19 using SHERLOCK

diagnostics. *medRxiv*, (2020).

33. J. P. Broughton, X. Deng, G. Yu, C. L. Fasching, V. Servellita, J. Singh, X. Miao,

J. A. Streithorst, A. Granados, A. Sotomayor-Gonzalez, K. Zorn, A. Gopez, E.

Hsu, W. Gu, S. Miller, C. Y. Pan, H. Guevara, D. A. Wadford, J. S. Chen, C. Y.

Chiu, CRISPR-Cas12-based detection of SARS-CoV-2. *Nat Biotechnol* **38**, 870-

874 (2020).

ACKNOWLEDGMENTS

We thank Bryan Willman for his support in fabricating customized heat blocks, Jan Gray

for his help with firmware development, Tom Blank for sharing the PCB fabrication

resources, and Dr. Liz Sanocki for the useful feedback on the software user interface.

We thank Shawna Cooper for sharing the graphics and content used in Audere's mobile

app's flu@home, which influenced the design of the first few screens of the Harmony

COVID-19 software. We thank Dr. Paul Yager and Steven Bennett for use of their

optical filters during the initial stage of device development. We thank Jason Tauscher

at the Washington Nanofabrication Facility for his assistance in cutting the plastic sheet

filters. The Washington Nanofabrication Facility is a National Nanotechnology

Coordinated Infrastructure (NNCI) site at the University of Washington with partial

support from the National Science Foundation via awards NNCI-2025489 and NNCI-

1542101. We thank Seattle Flu Study researchers Dr. Jay Shendure and Dr. Jase

Gehring for their helpful technical discussion. We thank Dr. Syamal Raychaudhuri, Dr.

Frances Chu from Inbios International, and Dr. Gwong-Jen J. Chang for the stimulating

discussion. We thank the Seattle Flu Study and the Seattle Coronavirus Assessment

Network (SCAN) teams led by Principal Investigators: Helen Y. Chu, MD, MPH, Michael

Boeckh, MD, PhD, Janet A. Englund, MD, Michael Famulare, PhD, Barry R. Lutz, PhD,

Deborah A. Nickerson, PhD, Mark J. Rieder, PhD, Lea M. Starita, PhD, Mathew

Thompson, MD, MPH, DPhil, Jay Shendure, MD, PhD and Trevor Bedford, PhD for

providing specimens for testing. **Funding**: This work was supported by the Seattle Flu

Study (funded by Gates Ventures) and the National Institutes of Health (R01AI140845;

5R61AI140460-03). We thank the Washington Entrepreneurial Research Evaluation

and Commercialization HUB program (WE-REACH, U01 HL152401) and their matching

grant partners for partly supporting reagents, supplies, and personnel. I.T.H. was

supported in part by the National Institute of General Medical Sciences of the National

Institutes of Health under Award Number T32GM008268. This work does not reflect the

views of the funders. The funders were not involved in the design of the study, and

funders do not have any ownership over the management and conduct of the study, the

data, or the rights to publish. **Author contributions:** N.P. developed lyophilized RT-

LAMP and outlined the overall plan for experiments and data visualization presented in

this manuscript. R.G.A. developed a mobile software application for operating the

device and analyzing results in real-time. M.R. developed the heater and fluorescent

reader device. E.K. designed the RT-LAMP assay primers and probes and engineered

polymerase. E.K., I.T.H., and Q.W. synthesized polymerase and provided usability

feedback during the development of the Harmony COVID-19 system. I.T.H. and Q.W.

prepared *in vitro* RNA transcripts. J.H.K. and V.L. led the usability study. N.P., A.K.O.,

and C.B. tested clinical and contrived specimens. R.G.A., N.P., A.K.O., and J.H.K.

analyzed the data. I.T.H. and Q.W. prepared the kits and blinded mock samples for

usability testing. D.L. developed housing units to integrate the cell phone, sample

preparation station, and the device. L.M.S. and P.D.H. designed and characterized the

clinical specimen panel used in this study. M.T. oversaw the usability study. B.R.L.

oversaw the development and evaluation of the Harmony COVID-19 system. All authors

contributed to writing this manuscript and approved the final version. **Competing**

interest: Provisional patent applications have been filed on several components of the

Harmony COVID-19 system. N.P., R.G.A., M.R., E.K., Q.W., I.T.H., D.L., and B.R.L. are

inventors on one or more provisional patent applications. N.P., R.G.A., M.R., E.K.,

Q.W., I.T.H., J.H.K., A.K.O., C.B., D.L., and B.R.L. anticipate forthcoming equity in a

startup company that has licensed related technology and supports ongoing work in the

B.R.L. laboratory at the University of Washington but played no role in the study. M.T. is

on the Advisory Board for Visby Medical which produces tests for COVID-19 and has

received reimbursement for this work. He has also received reimbursement for medical

advice to Roche Molecular Diagnostics and Inflammatix. **Data and materials**

availability: All data are presented in the main text and supplementary information.

Code availability: Sequence alignment and primer design was performed using

Geneious 8.1.9 (Auckland, New Zealand). CFX-Maestro (BioRad, Hercules, CA) was

used to analyze the RT-PCR results. TapeStation Software (Agilent, Santa Clara, CA)

was used to visualize fragments of synthetic RNA. A provisional patent application was

filed regarding aspects of the cell phone application. The data analysis algorithm is

described in the manuscript.

FIGURE CAPTIONS:

Fig. 1 Harmony COVID-19 workflow, analytical performance, and interpretation.

(**A**) User workflow. A nasal swab is collected and eluted in the rehydration buffer using

either a unified sampler-dispenser (shown) or a tube-and-bulb method (**Fig. 6**). The

swab eluate is then transferred into the reaction tube to rehydrate lyophilized, pre-

loaded RT-LAMP reagents. Users follow the instructions on the cell phone app to record

the sample identity, insert the tube in the test slot, and close the device. Four samples

can be analyzed in parallel. (Photo credits: a1-a4, Mark Stone at the University of

Washington and a5, Christopher Snyder at North Seattle College). (**B**) Examples of on-

device analysis. Lyophilized reagents were rehydrated with the eluate from swabs

spiked with 0, 200, 2000, or 20,000 copies of SARS-CoV-2 RNA, run on the device, and

analyzed in real time. The samples with SARS-CoV-2 RNA at 2000, 200, and 20

copies/reaction (**rxn**) were reported as positive by software at 27 min, 30 min, and 41

min, respectively; after 60 min the NTC reaction was classified as negative. (**C**) Time-to-

result. Individual detection time points ($n = 3$) are plotted. Variation in detection time

increases as samples approach the detection limit. (**D**) Diagnostic algorithm. Harmony

COVID-19 software calls samples as positive, negative, or indeterminate based on

detection of the three regions in nucleocapsid gene (NC1 overlapping with the CDC N1

region, NC2, and NC3 overlapping with the CDC N2 region) and the engineered IAC

sequence.

A

B **SARS-CoV-2 RNA tested on a commercial real-time thermal cycler using dried reagents**

C

D

E **SARS-CoV-2 RNA in the presence of simulated nasal matrix tested on a commercial real-time thermal cycler using dried reagents**

Fig. 2 Lyophilized RT-LAMP and its analytical sensitivity.

(**A**) To set up the assay, a sample in elution/rehydration buffer containing

magnesium, Thermopol buffer, and detergents is added to rehydrate the lyophilized RT-

LAMP reagents in a single step. (**B**) Real-time amplification signal of RT-LAMP

reactions containing SARS-CoV-2 RNA (**NTC**; no template control), 10, 15, 20, 200,

2000, 2×10^4, or 2×10^5 copies/40μL reaction (**rxn**). The left panel shows the average (*n =*

3) FAM signal detecting SARS-CoV-2. *Only 2/3 replicates of 10 copies/rxn amplified so

the average was from duplicate reactions. The right panel shows TEX 615 signal

detecting the internal amplification control (IAC). The IAC was detected in the NTC (*n =*

3) and in the single 10 copies/rxn that did not detect SARS-CoV-2. (**C**) Time to detection

of SARS-CoV-2 and IAC targets reported by the real-time thermal cycler. Individual data

points are plotted. Note that only 2/3 replicates of 10 copies/rxn amplified. IAC signals

were properly detected in NTC (*n = 3*) and 1 of the 3 replicates of 10 copies/rxn

undetected for SARS-CoV-2. (**D**) Evaluation of analytical sensitivity at 20 copies/rxn of

SARS-CoV-2 RNA (*n = 40*), performed in two different runs (*n = 20* each) with two

different serially diluted RNA samples. Time-to-result of individual samples are plotted

along with medians (middle lines of the boxes), interquartile ranges (edges of the

boxes), ranges (the ends of whiskers), and outliers (data points outside the whiskers).

(**E**) Impact of nasal matrix. SARS-CoV-2 RNA at 0, 40, or 100 copies/rxn was amplified

in lyophilized RT-LAMP in the presence of simulated nasal matrix (*n = 3*). All data was

812   measured every 13s using FAM and TEX 615 channels, by a real-time thermal cycler in

813   1h reactions at 63.3°C, and (**C**).

Fig.3 Overview of Harmony COVID-19 hardware.

(**A**) Plastic case cradles the cell phone (removable and connected by a spring cable),

mounts the heater/reader device, and houses a Charge-Plus USB-C connector hub (not

shown). A sample station holds the sample and reaction tube during processing and is

detachable to allow cleaning. Weight: 266g housing, 104g heater/reader device (total

<0.5kg). Dimensions: 205mm x 167.5mm x 125mm housing, 30mm x 120mm x 50mm

heater/reader device. (**B**) The heater/reader device contains an aluminum block with

wells for four samples (0.2mL reagent tubes) and is heated from the bottom by a

resistive heater made from serpentine conductive traces on a printed circuit board. In

the middle of the heater, a temperature sensor (Class B Platinum RTD) is used to

measure the heat block temperature. Power to the heater is supplied by a MOSFET and

modulated by varying the PWM duty cycle of the MOSFET. (**C**) Temperature profile

after the lid opening throughout a 60-min assay run. The microcontroller

(die) is measured to ensure the electronics are not overheated. (**D**) Lid heater, LED, and

detector. A heater (85°C) on top of the tube prevents condensation on the tube lid. The

lid heater is spring loaded to apply a preload force to the tubes to ensure good thermal

contact and contains pass-through holes for excitation LEDs. (**E**) Spectral

characteristics of the detection system. Blue and yellow LEDs provide excitation for

FAM and TEX 615, respectively, and photodetectors on each side detect light passing

through emission filters (spectral information from manufacturers(*21-23*)). The LEDs are

operated independently (only one LED is illuminated at a given time). (**F**) Effect of

thermostable inorganic pyrophosphatase (**TiPP**) on RT-LAMP signal in the Harmony

device. Normalized signal of negative control samples using the RT-LAMP formulation

with and without TiPP (*n = 1* each) at 64°C.

Fig. 4 Cell phone user interface and result reporting.

The Android Harmony application guides the user through steps to set up and run the

test. (**A**) Intended use of the device. (**B**) Instructions for the user to prepare samples.

(**B**) Selection of the number of samples. (**D**) Collection of sample identifiers by barcode,

photo capture, or manual typing. (**E**) Instruction to insert the tube when the temperature

of the device reaches the reaction temperature. (**F**) Real-time analysis during the test

run. (**G**) Positive results are reported as soon as they are detected. (**H**) Negative and

IND results are reported at the end of the run time.

Fig. 5 Harmony COVID-19 performance on clinical and blinded contrived specimens.

(**A**) Detection time called by Harmony COVID-19 software for the analysis of purified RNA extracted from human nasal specimens from 101 patients presenting respiratory symptoms. Stored specimens were re-tested by RT-qPCR using N1 and N2 CDC primers; results matched previous results in 30 previous positive specimens (positive for N1 and N2) and 68 previous negative specimens, with three previous positive

specimens classified as inconclusive (INC) because they were negative for either CDC

N1 or CDC N2 by RT-qPCR. Samples are ranked from left to right by increasing SARS-

CoV-2 concentrations as determined by RT-qPCR. Extracted RNA from specimens was

analyzed by Harmony COVID-19 (10μL RNA in 40μL RT-LAMP dry reagents, $n = 2$).

Samples were classified as positive by Harmony only if both replicates were detected.

The classification results by Harmony were compared to RT-qPCR using CDC primers

and probes (5μL RNA in 20μL RT-qPCR reaction). (**B**) Organisms in clinical samples

collected from individuals presenting with respiratory symptoms were quantified using

OpenArray, as previously described(*16*). High quantification cycle values indicate low

concentrations. All these specimens were correctly identified as SARS-CoV-2 negative

by Harmony. (**C**) Summary table for the sensitivity and specificity of the Harmony

COVID-19 system using extracted RNA from clinical specimens (RT-qPCR INC

samples excluded). (**D**) Blinded analysis of XPRIZE contrived sample panel. The assay

was run for 90 min (30 min longer than **Fig. 5A** to accommodate inhibitors that may be

present in these blinded samples). The table below shows the detectable samples over

the total number of tested technical replicates. (**E**) Summary table for the sensitivity and

specificity of the Harmony COVID-19 system on the XPRIZE contrived samples.

G   **Performance with *transfer pipettes***

	TP	TN	FP	FN	IND	% Accuracy	% IND
LPs	5	5	0	0	0	100	0
HCWs	9	9	0	1	1	95	5

H   **Performance with *unified dispenser***

	TP	TN	FP	FN	IND	% Accuracy	% IND
LPs	2	3	0	2	3	71	30
HCWs	7	10	0	2	1	89	5

Fig. 6 Usability study of Harmony COVID-19 workflow including two sample transfer methods at the POC.

(**A**) Study design. (**B**) Illustration of the first sample transfer method including a volumetric transfer pipette (40µL), a nasal swab, and a pre-loaded buffer vial. **video S1** demonstrates this workflow. Briefly, swabs are manually rubbed on the side of the tube for 30 seconds, soaked for 1 minute, and removed. The pipette is then used to transfer the swab eluate to rehydrate the lyophilized RT-LAMP reaction tube. (**C**) Illustration of the second sample transfer method option using a unified dispenser, which integrates a swab, buffer container, and a dropper in a single device. The contained buffer is released to elute the swab sample by cracking a conduit, the user agitates the fluid by shaking the tube, and a dropper tip allows the use to transfer two drops of fluid to the reaction tube by squeezing the body of the device. **video S2** demonstrates this workflow. (**D**) Volume transferred by each method performed by healthcare workers (**HCWs**) or laboratory personnel (**LPs**). Individual volume measurements are plotted along with medians (middle lines of the boxes), interquartile ranges (edges of the boxes), and ranges (the ends of whiskers). **e** and **f**, Assay performance on blinded contrived swabs (one negative swab and one positive swab with SARS-CoV-2 DNA at 1,000 copies/swab, corresponding to 100 copies/rxn) by LPs ($n = 5$) and untrained HCWs ($n = 10$) using transfer pipettes, (**E**) or unified dispensers, (**F**) The usability experiment written protocol is available on protocol.io (https://dx.doi.org/10.17504/protocols.io.bkvskw6e) and as a visual demonstration in

video S1 and video S2. (**G**) Performance summary for the transfer pipette method. (**H**)

Performance summary for the unified dispenser method.

TABLE CAPTIONS:

Table 1 Feature comparison between the Harmony COVID-19 system and other

assays. (**A**) Comparison to the U.S. CDC assay.(*9*) Full cost calculations for reagents

and devices are enclosed in **tables S3** and **table S4**.

Item	Standard RT-PCR assay (based on the U.S. CDC protocol)(*9*)	Covid-19 Harmony
SARS-CoV-2 primer detection	Separate reactions for N1 and N2	Multi-target redundancy amplifying three regions of the N gene in a single reaction tube
Process control	Human RP gene	Engineered internal control
LoD	1-3.2 copies/μL from extracted RNA	0.5 copies/μL (20 copies/40μL rxn) from synthetic RNA; 1 copies/μL (40 copies/40μL rxn) from extracted RNA from VTM; 2.5 copies/μL (100 copies/40μL rxn) from contrived nasal samples
Consumable cost	$12.94 ($6 extraction kit and $6.94 for RT-PCR Taq Path/IDT probes)	$8.00
Easy to use reagents	No	Yes
Batch size	24 specimens	Not required, run up to 4 samples
Equipment cost	> $5000 qPCR machine	$247 customized heater/reader
Time for sample-to-result	260 min	21-91 min

Hands-on: 120 min	Hands-on: 1 min for direct amplification
Wait-time: 120 min	Wait-time: 20-45 min for positive samples, but 90 min
Interpretation: 20 min	is required to confirm true negative

912 (**B**) Comparison of Harmony COVID-19 to other isothermal assays for SARS-CoV-2.

Published assays	Amplification chemistry	Multi-target redundancy in a single tube	Reported LoD	User-friendly devices with ready-to-use reagents and a closed system	Demonstration of use by HCWs
Harmony COVID-19 (This study)	RT-LAMP	Yes	0.5-2.5 copies/μL	Yes	Yes
A Alekseenko *et. al.* 2021(*24*)	RT-LAMP	No	10 copies/μL	No	No
BA Rabe and C Cepko(*25*)	RT-LAMP	No	50 copies/μL	No	No
S Wei, *et. al.*(*26*)	RT-LAMP	No	2.5 copies/μL	No	No
D Thi, *et. al.* (*27*)	RT-LAMP	No	5 copies/μL	No	No
L Bokelmann *et. al.* (*28*)	RT-LAMP	No	5-20 copies/μL	No	No
W Yamaziki *et. al.* (*29*)	RT-LAMP	Yes	25 copies/μL	No	No
J Qian *et. al.*(*30*)	RPA	Yes	0.5 copies/μL	No	No

M Patchsung *et.* *al.*(*31*)	SHERLOCK	No			No	No
			2.1 copies/*μ*L			
J Joung *et.* *al.*(*32*)	SHERLOCK	No			No	No
			2 copies/*μ*L			
J Broughton *et.al.* (*33*)	CRISPR cas12	No			No	No
			10 copy/*μ*L			

SUPPLEMENTARY INFORMATION:

fig. S1 Effects of excipients on fresh RT-LAMP reactions tested on a commercial real-

time thermal cycler.

fig. S2 Cross-reactivity of MERS and SARS in lyophilized RT-LAMP.

fig. S3 Heat block used in Harmony COVID-19 device.

fig. S4 The design of optical and heater circuit boards for the Harmony COVID-19

device.

fig. S5 Circuit board assembly and required parts

fig. S6 Device assembly

video S1 Demonstration of transfer pipette workflow incorporated with Harmony

COVID-19.

video S2 Demonstration of the integrated sampling system workflow with Harmony

COVID-19

table S1 Primers, probes, and control sequences.

table S2 Feedback from the HCWs

table S3 Detailed reagent and device cost at a production scale of 10,000 units.

table S4 Consumable costs per test

SUPPLEMENTARY INFORMATION

Trehalose can stabilize several enzymes, but we found that 2.5% (*w/v*) trehalose

resulted in a slower reaction at 63°C, the optimal reaction temperature of the excipient-

free RT-LAMP. An increase of reaction temperature to 65°C can speed up the

trehalose-containing RT-LAMP reactions but resulted in unreliable detection at 20 RNA

copies/reaction (**fig. S1**).

A

Target (copies/ reaction)	min to detection							
	65 °C		63 °C		59 °C		55 °C	
	SARS-CoV-2	IAC	SARS-CoV-2	IAC	SARS-CoV-2	IAC	SARS-CoV-2	IAC
0	N/A	27.3, 27.7	N/A	31.8, 30.7	N/A	44.7, 42.6	N/A	N/A
20	N/A	29.8, 27.5	N/A, 31.63	30.6, 32.1	N/A, 43.0	42.0, 42.8	N/A	N/A, 60.4
200	N/A	27.3, 27.4	N/A, 27.86	29.4, 39.5	N/A, 43.2	47.9, 40.4	N/A	N/A, 62.0
2000	24.7, 28.6	N/A	28.0, 28.2	30.3, 32.8	N/A, 51.0	43.3, 41.8	N/A	N/A, 60.3

% mannitol	Target (copies/reaction)	SARS-CoV-2 (min to detection)	IAC (min to detection)
0	0	N/A	33.0, 33.0
	20	25.0, 25.7	N/A
2.5	0	N/A	33.9, 34.0
	20	26.3, 26.3	N/A

fig. S1 Effects of excipients on fresh RT-LAMP reactions tested on a commercial

real-time thermal cycler. (**A**) Time to detection of SARS-CoV-2 RNA and IAC targets

in the RT-LAMP containing 2.5% *(w/v)* trehalose and 0-2000 copies of SARS-CoV-2

RNA/40µL reaction. N/A means undetectable. For each condition, two technical

replicates were run at 4 different reaction temperatures (i.e., 55°C, 59°C, 63°C, and

65°C). (**B**) Time to detection of SARS-CoV-2 RNA and IAC targets in the RT-LAMP

reactions containing 0 or 20 copies of SARS-CoV-2 RNA/reaction, with and without

2.5% (*w/v*) mannitol, at 63°C.

non-SARS-CoV-2 RNA (copies/reaction)	SARS-CoV-2 RNA (copies/reaction)	min to detection	
		SARS-CoV-2	**IAC**
4000 copies SARS-CoV-1	0	N/A	29.0, 30
4000 copies SARS-CoV-1	100	23.5, 24.1	N/A
4000 copies MERS	0	N/A	29.8, 30.1
4000 copies MERS	100	24.7, 24.7	N/A

fig.S2 Cross-reactivity of MERS and SARS in lyophilized RT-LAMP.

Detection time (min) of SARS-CoV-2 RNA and IAC targets in the presence of 4000

copies of either SARS-CoV-1 RNA or MERS RNA in 40µL RT-LAMP reactions at 63°C.

Two technical replicates were conducted in each condition. In the reactions without

SARS-CoV-2 RNA, we did not observe amplification of FAM signal but observed IAC

amplification indicating the amplification reaction was functioning properly in each

replicate. 100 copies of SARS-CoV-2 RNA were amplified in each positive control

replicate, indicating proper function of SARS-CoV-2 amplification in this master mix.

fig. S3 Heat block used in Harmony COVID-19 device. Drawing credit: Bryan

Willman.

fig. S4 The design of optical and heater circuit boards for the Harmony COVID-19

device. (**A**) LED board (**B**) the detector board

fig. S5 Circuit board assembly and required parts.

(**A**) LED board. (**B**) LED board assembled to the lid heater board. (**C**) Custom-cut filter

pieces. (**D**) Detector board and the main board. Each device require the following parts:

thick film resistors (RCL12251R20FKEG, RCL12252R20FKEG,

CRCW08050000Z0EBC and RCL12254R70FKEG from Vishey; RN73C1J75RBTDF

from TE Connectivity; FTS-105-03-F-DV from Samtec; CR0402AJW-472GAS from

Bourns), thin film resistors (RN73H1ETTP3003B25 from KOA Speer; ERJ-2RKF22R0X

from Panasonic), multilayer ceramic capacitors (C0402C104M4RACAUTO, KEMET;

0603YC105KAT2A, AVX), multilayer ceramic capacitor (GRM188R60J226MEA0D,

Murata), USB connectors (10118193-0001LF and 10118192-0001LF, FCI / Amphenol),

FFC & FPC connector (52745-1497, Molex), standard yellow LEDs (LY E63B-CBEA-26-

1-Z, Osram Opto Semiconductor), standard blue LEDs (150141BS63140, Wurth

Elektronik), board-to-board & mezzanine connector (CLP-105-02-F-D and FLE-105-01-

G-DV-K-TR, Samtec), FFC/FPC jumper cables (15166-0143, Molex), FFC & FFC

connector (52559-1452, Molex), 2 headers & wire Housings (FTSH-105-01-F-DH,

Samtec), MOSFET (FDMA410NZ, ON Semiconductor), 2 board-mount temperature

sensors (PTS060301B100RP100 from Vishay), ARM Microcontrollers (CY8C5888LTI-

LP097, Cypress Semiconductor), Photodiodes (SFH 2201, Opto Semiconductor).

fig. S6 Device assembly.

(**A**) Top part (**B**) Bottom part of the device are assembled using 10 screws, 2

compression springs, and 2 torsion springs (McMaster-Carr, Elmhurst, IL) including:

Torsion Spring 90 Degree Angle, Left-Hand Wound, 0.204" OD (9271K109), Torsion

Spring 90 Degree Angle, Right-Hand Wound, 0.204" OD (9271K143),Black-Oxide Alloy

Steel Socket Head Screw M3 x 0.5 mm Thread, 5 mm Long (91290A110), Black-Oxide

Alloy Steel Socket Head Screw M3 x 0.5 mm Thread, 10 mm Long (91290A115), Black-

Oxide Alloy Steel Socket Head Screw M3 x 0.5 mm Thread, 15 mm Long (91290A572),

Black-Oxide Alloy Steel Socket Head Screw M3 x 0.5 mm Thread, 20 mm Long

(91290A123), Black-Oxide Alloy Steel Socket Head Screw M3 x 0.5 mm Thread, 25 mm

Long (91290A125), Black-Oxide Alloy Steel Socket Head Screw M3 x 0.5 mm Thread,

30 mm Long, Partially Threaded (91290A130), Music-Wire Steel Compression Springs

0.875" Long, 0.36" OD, 0.296" ID (9434K73).

1004

1005

1006 **video S1**

1007 Demonstration of transfer pipette workflow incorporated with Harmony COVID-19

1008 **video S2**

1009 Demonstration of the integrated sampling system workflow with Harmony COVID-19

1010 Both can be played from this slide presentation:

1011

1012

1013

1014 **table S1 Primers, probes, and control sequences.**

1015 For primers and probes F2/B2 sequences are underlined, non-template linker

1016 sequences are italicized, and adapter sequences are in bold.

1017

SARS-Cov-2 NC1 Primers	Sequence (5' to 3')
NC1 FIP	CCACTGCGTTCTCCATTC*TTTT*<u>CCCCGCATTACGTTTGGT</u>
NC1 BIP	GCGATCAAAACAACGTCGG*TTAT*<u>TGCCATGTTGAGTGAGAGCG</u>
NC1 LF	TGGTTACTGCCAGTTGAATCT
NC1 LB + T Adapter	**ACCAACACCTCACATCACACATAATA**GGTTTACCCAATAATACTG CGTCTTG
NC1 F3	TGGACCCCAAAATCAGCG
NC1 B3	ATCTGGACTGCTATTGGTGTTA
SARS-CoV-2 NC2 Primer	Sequence
NC2 FIP	CAGCTTCTGGCCCAGTTCCT<u>GTGGTGGTGACGGTAAAATG</u>
NC2 BIP	CTTCCCTATGGTGCTAACAAAG*T*<u>CCAATGTGATCTTTTGGTGTATT CA</u>
NC2 LF	GTAGTAGAAATACCATCTTGGACT
NC2 LB + T Adapter	**ACCAACACCTCACATCACACATAATA**ATATGGGTTGCAACTGAG GGAG
NC2 F3	CTACTACCGAAGAGCTACCAG
NC2 B3	GCAGCATTGTTAGCAGGATTG
SARS-CoV-2 NC3 Primers	Sequence
NC3 FIP	TGTGTAGGTCAACCACGTTC*T*<u>GCTTCAGCGTTCTTCGGA</u>

NC3 BIP	GTGCCATCAAATTGGATGACAAAG<u>GTTTTGTATGCGTCAATATGCT</u> <u>TATTCAG</u>
NC3 LF + T Adapter	**ACCAACACCTCACATCACACATAATA**TCCATGCCAATGCGCGAC A
NC3 LB	CCAAATTTCAAAGATCAAGTCAT
NC3 F3	GACCAGGAACTAATCAGACAAG
NC3 B3	GCTTGAGTTTCATCAGCCTTC
IAC (NC1) primer	Sequence
IAC FL + C Adapter	**ACCACACCTACCACCACTAATAACTAA**CTCCAGCCATCCTCACC ATC
Target UDP	Sequence
CoV UDP Probe	FITC – CCATCAGCACCAAGACTACCCACCTCGCCACCAA**ACCAACACCT** **CACATCACACATAATA**
CoV UDP Quencher	TTGGTGGCGAGGTGGGTAGTCTTGGTGCTGATGG– Iowa Black® FQ
Control UDP	Sequence
IAC UDP Probe	Tex615 – CCTGACCACTTCCGAACCCAACCACCTACGACAG**ACCACACCTA** **CCACCACTAATAACTAA**
IAC UDP Quencher	CTGTCGTAGGTGGTTGGGTTCGGAAGTGGTCAGG – BHQ2
IAC Template	Sequence
IAC (NC1) ssDNA	AAT GGA CCC CAA AAT CAG CGA AAT GCA CCC CGC ATT ACG TTT GGT GGA CCC TCT GGA GTC AAT GGG TGG TGC AGA AAT GGA GAA CGC AGT GGG GCG CGA TCA AAA CAA CGT CGG CCC CAA GTT GAT

CTC CAG CCA TCC TCA CCA TCG TTC ACC GCT CTC ACT CAA CAT

GGC AAG AAT TAA CAC CAA TAG CAG TCC AGA TG

1018

1019

Sample transfer methods at the POC

Volumetric transfer pipettes are used in POC tests, but we have not identified a unified

dispenser used in commercial pathogen tests. A unified dispenser integrating the swab

and the buffer container in a single unit could reduce opportunities for sample mix-up

when multiple samples are processed simultaneously. A simple workflow is crucial,

especially in busy settings like clinics. However, in our hands, the in-house built

dispenser led to variable dispensed fluid volumes and had a higher failure rate than

those of the transfer pipette method. While the unified dispenser has many attractive

features, we would not recommend using this in-house assembled dispenser unit until

the method has been optimized to achieve a more accurately dispensed volume.

1030

table S2 Feedback from the HCWs

Among HCWs, 30% (3/10) reported problems dispensing the fluid using the unified

system. However, 20% (2/10) of HCWs agreed that the unified dispenser offered an

advantage in its similarity to other tools used in healthcare settings, and 30% (3/10)

HCWs were concerned about contaminating the sample or the environment with the

transfer pipette compared to the unified dispenser system. Only 1/10 (10%) HCW

preferred the smallest tube (0.2mL) for either method, and 5/10 (50%) reported that

larger (1.5mL) tubes were helpful for the unified system, while 40% (4/10) of HCWs said

receptacle size did not make a difference when using the transfer pipette, and none

reported preference for tube size when using the unified dispenser system. HCWs

reported higher confidence in correctly completing the second kit compared to the first

kit of each method, indicating a similar learning curve.

1043

1044

1045 (**A**) **User preference for reaction tube size**

1046 Note: Cells with 0% response were left empty to aid data visualization.

1047

Question	User response, n (%)				
	0.2 mL	0.5 mL	1.5 mL	0.5mL or 1.5mL	no difference
Which tube size were you most confident using with the unified dispenser swab?		4 (**40%**)	5 (**50%**)	1 (**10%**)	
Which tube size were you most confident using with the transfer pipette?	1 (**10%**)	4 (**40%**)	1 (**10%**)		4 (**40%**)

1048

1049 (**B**) **User responses to survey questions during sample transfer usability testing.**

1050 Users were asked to provide their response on a Likert scale: (1) Not at all, (2) Slightly,

1051 (3) Somewhat, (4) Fairly, (5) Completely. Note: Phrasing of the questions below was

1052 slightly modified to be clear outside of the context of the written protocol/survey (original

1053 survey here). Cells with 0% response were left empty to aid data visualization.

Question	User response, n (%)				
	(1)	**(2)**	**(3)**	**(4)**	**(5)**
How confident were you that you added the **correct amount of liquid** to each reaction tube using the **unified dispenser system?**			3 (**30%**)	3 (**30%**)	4 (**40%**)
How confident were you that you completed the protocol correctly using the **unified dispenser system** with the **first kit**?		2 (**20%**)	1 (**10%**)	4 (**40%**)	3 (**30%**)
How confident were you that you completed the protocol correctly using the unified dispenser system with the second kit?				5(**50%**)	5 (**50%**)
How confident were you that you added the correct amount of liquid to each reaction tube using the **transfer pipette**?			2 (**20%**)	2(**20%**)	6 (**60%**)
How confident were you that you completed the protocol correctly using the **transfer pipette** with the **first kit**?			3 (**30%**)	4 (**40%**)	3 (**30%**)
How confident were you that you completed the protocol correctly				5 (**50%**)	5 (**50%**)

using the **transfer pipette** with the second kit?		
How confident were you that you completed the **on-screen instructions correctly**?	1 (**10%**) 4 (**40%**) 5 (**50%**)	

(**C**) **User reported errors/challenges between two sample transfer methods.** Cells with no response were left empty to aid data visualization.

	Sample transfer method	
Reported error	Number of occurrences for the **unified dispensing system**	Number of occurrences for the **transfer pipette**
The transfer method was hard to aim at the receiving reaction tube.	1	
Transfer method dripped/leaked before dispensing to the reaction tube.	2	
The materials were too small or difficult to handle.		3
It was hard to execute specific instructions due to unfamiliarity with the sample transfer device.	2	1
Challenging to dispense a consistent amount of fluid.	3	

Not confident liquid was dispensed to the tube.	2
Concerned about contaminating samples or the environment.	3

table S3 Detailed reagent and device cost at a production scale of 10,000 units

Item	Supplier	Cost/device (US$)
Detector boards	Macrofab	$7 each x 2 ($14 total)
Main board	Macrofab	$25 each
LED board	Macrofab	$9 each
Lid Heater	Oshpark	$7 each
Heat block	Bryan Willman	$12 each
Housing	Xometry – HP MultiJet Fusion 3D printing, no volume discount	$50 (costs here should be reduced for scale-up production)
Red filters	Newport	$10 each, $40 in total
Green filters	Newport	$20 each, $80 in total
Assembly	N/A	$30 (half an hour assembly time at $60/hour cost)
Total		**$267 per unit**

table S4 Consumable costs per test

Item	Supplier	Costs per kit (US$)

Sampling components ($2 maximum)	Multiple sources	$2
Desiccant	Multiple sources	$0.5
PCR tube	Multiple sources	Negligible
DNA polymerase	Produced in-house	Negligible
Reverse transcriptase	New England Biolabs	$3.5
Thermostable inorganic pyrophosphatase	New England Biolabs	$0.23
Primers	Integrated DNA Technologies	$0.03
Fluorescent probe/quenchers	Integrated DNA Technologies	$0.24
Triton-X100	Sigma-Aldrich	Negligible
dNTPs	New England Biolabs	$0.38
Mannitol	OPS Diagnostics	Negligible
DL-Dithiothreitol (DTT)	Promega	Negligible
Nuclease-free water	VWR	Negligible
1X Tris low-EDTA buffer	VWR	Negligible
Rnasin ribonuclease inhibitor	Promega	$0.71
DNA internal amplification control	Integrated DNA Technologies	$0.01
Cost of goods		**$8.00**

1064

1065